SG11201608587QA - Potent and selective inhibitors of hepatitis c virus - Google Patents

Potent and selective inhibitors of hepatitis c virus

Info

Publication number
SG11201608587QA
SG11201608587QA SG11201608587QA SG11201608587QA SG11201608587QA SG 11201608587Q A SG11201608587Q A SG 11201608587QA SG 11201608587Q A SG11201608587Q A SG 11201608587QA SG 11201608587Q A SG11201608587Q A SG 11201608587QA SG 11201608587Q A SG11201608587Q A SG 11201608587QA
Authority
SG
Singapore
Prior art keywords
hepatitis
potent
virus
selective inhibitors
inhibitors
Prior art date
Application number
SG11201608587QA
Other languages
English (en)
Inventor
Steven J Coats
Richard Anthony Whitaker
Tamara Rosario Mcbrayer
Junxing Shi
Franck Amblard
Hongwang Zhang
Longhu Zhou
Raymond F Schinazi
Original Assignee
Cocrystal Pharma Inc
Univ Emory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cocrystal Pharma Inc, Univ Emory filed Critical Cocrystal Pharma Inc
Publication of SG11201608587QA publication Critical patent/SG11201608587QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG11201608587QA 2014-04-15 2015-04-15 Potent and selective inhibitors of hepatitis c virus SG11201608587QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461980016P 2014-04-15 2014-04-15
PCT/US2015/025903 WO2015160907A2 (en) 2014-04-15 2015-04-15 Potent and selective inhibitors of hepatitis c virus

Publications (1)

Publication Number Publication Date
SG11201608587QA true SG11201608587QA (en) 2016-11-29

Family

ID=54324704

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201608587QA SG11201608587QA (en) 2014-04-15 2015-04-15 Potent and selective inhibitors of hepatitis c virus

Country Status (14)

Country Link
US (1) US9926295B2 (hr)
EP (1) EP3131892A4 (hr)
JP (1) JP2017513852A (hr)
KR (1) KR20170002407A (hr)
CN (1) CN106661004A (hr)
AU (1) AU2015247706A1 (hr)
BR (1) BR112016023833A2 (hr)
CA (1) CA2945514A1 (hr)
IL (1) IL248318A0 (hr)
MX (1) MX2016013434A (hr)
PH (1) PH12016502039A1 (hr)
RU (1) RU2016144076A (hr)
SG (1) SG11201608587QA (hr)
WO (1) WO2015160907A2 (hr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
US9775831B2 (en) 2013-07-17 2017-10-03 Bristol-Myers Squibb Company Combinations comprising biphenyl derivatives for use in the treatment of HCV
WO2015184644A1 (zh) * 2014-06-06 2015-12-10 爱博新药研发(上海)有限公司 抑制丙肝病毒的化合物、药物组合物及其应用
WO2017023631A1 (en) 2015-08-06 2017-02-09 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
CA3096916A1 (en) * 2018-05-09 2019-11-14 Cocrystal Pharma, Inc. Combination therapy for the treatment of hepatitis c virus
CN109456375B (zh) * 2018-12-11 2019-10-22 枣庄学院 一种抑制丙肝病毒的含单糖基杂环类化合物及制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ587557A (en) * 2008-02-13 2012-04-27 Bristol Myers Squibb Co Imidazolyl biphenyl imidazoles as hepatitis c virus inhibitors
CA2751458C (en) * 2009-02-06 2018-06-05 Rfs Pharma, Llc Purine nucleoside monophosphate prodrugs for treatment of cancer and viral infections
US8377980B2 (en) * 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8859595B2 (en) * 2010-08-26 2014-10-14 Rfs Pharma, Llc Potent and selective inhibitors of hepatitis C virus
WO2012048421A1 (en) * 2010-10-14 2012-04-19 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor compounds
WO2012061248A2 (en) * 2010-11-01 2012-05-10 Rfs Pharma, Llc Novel specific hcv ns3 protease inhibitors

Also Published As

Publication number Publication date
CA2945514A1 (en) 2015-10-22
PH12016502039A1 (en) 2017-01-09
WO2015160907A2 (en) 2015-10-22
WO2015160907A3 (en) 2016-12-01
EP3131892A2 (en) 2017-02-22
RU2016144076A (ru) 2018-05-16
US9926295B2 (en) 2018-03-27
MX2016013434A (es) 2017-03-03
IL248318A0 (en) 2016-11-30
BR112016023833A2 (pt) 2017-10-10
EP3131892A4 (en) 2017-09-20
AU2015247706A1 (en) 2016-10-27
US20170029407A1 (en) 2017-02-02
CN106661004A (zh) 2017-05-10
JP2017513852A (ja) 2017-06-01
KR20170002407A (ko) 2017-01-06

Similar Documents

Publication Publication Date Title
HK1252697A1 (zh) 抗cd33抗體及其使用方法
HK1243463A1 (zh) 檢測rna病毒的組合物和方法
HK1252675A1 (zh) 抗cd33抗體及其使用方法
IL251450A0 (en) Preparations and methods for silencing hepatitis b virus gene expression
IL250415B (en) Antibodies against pd-l and methods of using them
ZA201608885B (en) Process and device for desulfurization-denitration of flue gas
IL278574B1 (en) Compounds acting on glycans and methods of using them
EP3240787A4 (en) Derivatives and methods of treating hepatitis b infections
HK1253049A1 (zh) 糖基相互作用化合物及其使用方法
HK1231402A1 (zh) 治療 型肝炎和 型肝炎病毒感染的方法
IL248318A0 (en) Selective inhibitors that have an effect on the hepatitis virus type c
PT3089971T (pt) Compostos e métodos de utilização
HK1249046A1 (zh) 治療b型肝炎病毒的方法
HK1254110A1 (zh) 用於檢測病毒的改善的組合物和方法
SG11201605915WA (en) Furo-3-carboxamide derivatives and methods of use
HK1249514A1 (zh) C型肝炎病毒聚合酶的抑制劑
GB201402169D0 (en) Viral inhibitors
ZA201703123B (en) Combination long acting compositions and methods for hepatitis c
PL2942121T3 (pl) Tłumik środkowy i sposób wytwarzania tłumika środkowego
EP3176814C0 (en) PHOTODETECTOR ARRANGEMENTS AND METHODS OF MAKING SAME
GB201403697D0 (en) Compounds and methods of use
EP3324959C0 (en) LICOFELON DERIVATIVES AND METHODS OF USE
GB201416797D0 (en) Contianer and method of use thereof
GB201507707D0 (en) Components and methods for formation of components